Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios

REFERENCES

• McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang T, Wolfert R, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new area. Urology 1995; 45: 729–44.
   PubMed Web of Science ®Google Scholar
• Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson 0, Petterson K, et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-l-antichymotrypsin. Clin Chem 1991; 37: 1618–25.
   Google Scholar
• Lilja H. Significance of different molecular forms of serum PSA. The free, non complexed forms of PSA versus that complexed to otrantichymotrypsin. Urol Clin North Am 1993; 20 (4): 681–6.
   Google Scholar
• Partin AW, Subong ENP, Kelley CA, Hortopan S, Ballentine Carter H, Chan DW, et al. Prospective analysis of free PSA to total PSA ratio (PSAFIPSAT) for prostate cancer detection and the clearance rate of PSAF after radical prostatectomy. J Urol 1996; 155 Suppl: 422A.
   Google Scholar
• Oesterling JE, Wojno KJ, England B, Vessela RL, Lange PH, Noteboom J, et al. A comparison of free to total PSA (F/T) ratio to total PSA for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer (CaP) using the Abbott AxSYM system. J Urol 1996; 155 Suppl: 240A.
   Google Scholar
• Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518–24.
   PubMed Web of Science ®Google Scholar
• Demura T, Shinoara N, Tanaka M, Enami N, Chiba H, Togashi M, et al. The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma. Cancer 1996; 77: 1137–43.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20.
   PubMed Web of Science ®Google Scholar
• Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II: retrospective analysis of free/total prostate specific antigen ratio, age-specific ranges, and PSA density. Urology 1995; 46: 779–84.
   Google Scholar
• Prestiagiacomo AF, Lilja H, Pederson K, Wolfed RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996; 156: 350–4.
   Google Scholar
• Brawer MK, Wener MH, Rittenhouse HG, Wolfed RL. Proportion of free form PSA explains the majority of bias between the IMx (Abbott) and Tandem (Hybritech) PSA assays. J Urol 1996; 155 Suppl: 424A.
   Google Scholar
• Carter HB, Partin AW, Luderer AA, Metter EJ, Landis P. Chan DW, et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 1997; 49: 379–84.
   Google Scholar
• Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA with pathologic features of prostatic carcinoma [abstract]. J Urol 1996; 155 Suppl: 415A.
   Google Scholar
• Stein A, Barak M, Mecz Y, Rubinov R. Serum free/total (F/T) PSA in LH-RH agonists treated prostate cancer patients. Br J Urol 1997; 80 Suppl 2: 279.
   Google Scholar
• Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2–12.
   PubMed Web of Science ®Google Scholar
• Brawn PN, Ayala AG, Von Eschenbach AC, Hussey DH, Johnson DE. Histologic grading of prostate adenocarcinoma. The development of a new system ratio is not superior to total PSA in the diagnosis of prostate cancer in the community setting [abstract]. J Urol 1996; 155 Suppl: 371A.
   Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiving operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.
   PubMed Web of Science ®Google Scholar
• Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnos-tic gray zone of total prostate-specific antigen. Urology 1995; 46: 187–94.
   PubMed Web of Science ®Google Scholar
• Klee GG, Lerner SE, Jacobsen SJ, Bergstrahl EJ, Lilja H. Pederson K. et al. Predictive flower of free:total PSA H, Pederson K, et al. Predictive power of free:total PSA and comparison with other methods. A preliminary study. Cancer 1982; 49: 525–32.
   Google Scholar
• Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign hyperplasia. Cancer 1997; 79: 104–9.
   Google Scholar
• Takayama TK, Vesalla RL, Lange PH. Newer applica-tions of serum prostate specific antigen in the manage-ment of prostate cancer. Semin Oncol 1994; 21: 542–53.
   Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860–4.
   PubMed Web of Science ®Google Scholar
• Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747–52.
   PubMed Web of Science ®Google Scholar
• Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate-specific antigen and otrantichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6.
   Google Scholar
• Christensson A, Björk T, Nilsson 0, Dahlen U, Matikainen M, Cocked ATK, et al. Serum prostate specific antigen complexed to otrantichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100–5.
   Google Scholar
• Elgamel AA, Cornillie F, van Poppet H, van Dorpe JA, Gero E, Haberzettl C, et al. Free/total PSA ratio (F/T) as a single test for detection of significant Tic prostate cancer. J Urol 1996; 155: 369A.
   Google Scholar